Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea

Infection Control and Hospital Epidemiology

Volumn 28, Issue 4, 2007, Pages 377-381

  Peled, Nir ^a   Pitlik, Silvio ^a,b   Samra, Zmira ^a   Kazakov, Arkadi ^a   Bloch, Yoram ^a   Bishara, Jihad ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CEPHALOSPORIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; LAXATIVE; PENICILLIN G; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; FECES ANALYSIS; FEMALE; HUMAN; HYPOALBUMINEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; ENTEROTOXINS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 34247550291     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/513723     Document Type: Article

References (25)

1. Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 2003; 52:259-263.
2. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician 2005; 71:921-928.
3. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257-262.
4. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-353.
5. Loo GV, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449.
6. Kyne I, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-397.
7. Samra Z, Talmor S, Bahar J. High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalised patients with gastrointestinal diseases. Diagn Microbiol Infect Dis 2002; 43:189-192.
8. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989; 29:307-335.
9. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
10. Cooper GS, Lederman MM, Salata RA. A prediction model to identify Clostridium difficile toxin in hospitalized patients with diarrhea. Am J Gastroenterol 1996; 91:80-84.
11. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and Clostridium difficile associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162:678-684.
12. Kyne L, Sogioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23:653-659.
13. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin associated diarrhea. Infect Control Hosp Epidemiol 1990; 11:283-290.
14. Modena S, Bearelly D, Swartz K, Friedenberg F. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005; 26:685-690.
15. Wanathia A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002; 34: 1585-1592.
16. Bartlett JG. Leukocytosis and Clostridium difficile-associated diarrhea. Am J Gastroenterol 2000; 95:3023-3024.
17. Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137-3141.
18. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004; 171:33-38.
19. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile associated diarrhea. J Hosp Infect 2003; 54:243-245.
20. Williams C. Occurance and significance of gastric colonization during acid inhibitory therapy. Best Pract Res Clin Gastroenterol 2001; 15:511-521.
21. Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996; 100:487-495.
22. Katz DA, Bates DW, Rittenberg E, et al. Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea. J Gen Intern Med 1997; 12:57-62.
23. Hornbuckle K, Chack A, Lazarus HM, et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998; 9:307-311.
24. Talbot RW, Walker RC, Beart RW Jr. Changing epidemiology diagnosis and treatment of Clostridium difficile toxin associated colitis. Br J Surg 1986; 73:457-460.
25. Gebhard RL, Gerding DN, Olson MM, et al. Clinical and endoscopic findings in patients early in the course of Clostridium difficile associated pseudomembranous colitis. Am J Med 1985; 78:45-48.